228 related articles for article (PubMed ID: 32970216)
1. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [
Seifert R; Kessel K; Schlack K; Weber M; Herrmann K; Spanke M; Fendler WP; Hadaschik B; Kleesiek J; Schäfers M; Weckesser M; Boegemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1200-1210. PubMed ID: 32970216
[TBL] [Abstract][Full Text] [Related]
2. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy.
Seifert R; Kessel K; Schlack K; Weckesser M; Kersting D; Seitzer KE; Weber M; Bögemann M; Rahbar K
Theranostics; 2021; 11(17):8143-8151. PubMed ID: 34373733
[No Abstract] [Full Text] [Related]
3. SUV
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Schlötelburg W; Michalski K; Rowe SP; Pomper MG; Buck AK; Eberlein U; Werner RA
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3465-3474. PubMed ID: 37272956
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
5. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
6. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
7. Change in total lesion PSMA (TLP) during [
Burgard C; Hein C; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S; Rosar F
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):885-895. PubMed ID: 37889298
[TBL] [Abstract][Full Text] [Related]
8. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
9. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy.
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4077-4088. PubMed ID: 34041564
[TBL] [Abstract][Full Text] [Related]
11. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving
Seifert R; Seitzer K; Herrmann K; Kessel K; Schäfers M; Kleesiek J; Weckesser M; Boegemann M; Rahbar K
Theranostics; 2020; 10(17):7812-7820. PubMed ID: 32685021
[No Abstract] [Full Text] [Related]
12. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging and biochemical response assessment after a single cycle of [
Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
[No Abstract] [Full Text] [Related]
14. Evaluation of thresholding methods for the quantification of [
Kim M; Seifert R; Fragemann J; Kersting D; Murray J; Jonske F; Pomykala KL; Egger J; Fendler WP; Herrmann K; Kleesiek J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2196-2209. PubMed ID: 36859618
[TBL] [Abstract][Full Text] [Related]
15. Role of baseline
Telli TA; Ozguven S; Alan O; Filizoglu N; Ozturk MA; Sariyar N; Isik S; Arikan R; Demircan NC; Basoglu T; Cetin IA; Ones T; Ercelep O; Dane F; Yumuk PF
Ann Nucl Med; 2022 Nov; 36(11):964-975. PubMed ID: 35997890
[TBL] [Abstract][Full Text] [Related]
16. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
17. Extended therapy with [
Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
[TBL] [Abstract][Full Text] [Related]
18.
Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649
[TBL] [Abstract][Full Text] [Related]
19. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
Gafita A; Rauscher I; Weber M; Hadaschik B; Wang H; Armstrong WR; Tauber R; Grogan TR; Czernin J; Rettig MB; Herrmann K; Calais J; Weber WA; Benz MR; Fendler WP; Eiber M
J Nucl Med; 2022 Nov; 63(11):1651-1658. PubMed ID: 35422442
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]